9-76-07

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

MAR 2 3 2007 e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/594,194	
TRANSMITTAL	Filing Date	September 25, 2006	
FORM	First Named Inventor	May Han	
	Art Unit	1657	
(to be used for all correspondence after initial filing)	Examiner Name	Not yet assigned	

Total	Number of	f Pages in ∃	This Submission	7	Attorney Docket Numb	er	GEN/0	33	
		<u>-</u>		ENC	LOSURES (Check	all t	hat apply	·)	-
	Fee Tran	smittal Fo	om		Drawing(s)				After Allowance Communication to TC
	Amendm Amendm	n of Time Abandonr	declaration(s)		Petition Petition to Convert to a Provisional Application Power of Attorney, Revoc Change of Corresponden Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table of	catior	ddress		Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): 1. PTO/SB/08A 2. Copies of non-US patent references 3. Postcard
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53			conne No. 00	Director is hereby autection with filing of the 01581-0281. A duple	ese icate	papers e copy o	to Dep	payment of any fees required in posit Account No. 06-1075, Order etter is transmitted herewith.	
		T			OF APPLICANT, AT	FOR	NEY, O	R AG	ENT
Firm Na	ıme	Fish &	Neave IP Gro	up of Ro	opes & Gray		_		
Signatur	re	Ja	Me T. G	um	MEGN.				
Printed	name	Jane T	. Gunnison						
Date		March	23, 2007			R	leg. No.	38,47	9
	CERTIFICATE OF EXPRESS MAILING – EV930026010US I hereby certify that this paper/fee and the listed enclosures are being deposited with the United States Postal Service "EXPRESS MAIL								
POST C	POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.								
Signatur	re		Shall	(m)	15.8				>
\ Typed or	r printed i	name	Isat	ta B. S	smith				Date March 23, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc. www.FormsWorkflow.com

Date | March 23, 2007

Typed or printed name





Attorney Docket No.: GEN/033

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: May Han

Application No.

: 10/594,194

Confirmation No.:

7781

Group Art Unit

: 1657

Examiner

: Not Yet Assigned

Filed

September 25, 2006

For

: METHODS FOR MEASURING ENZYME ACTIVITIES

IN CELLS, BLOOD, TUMORS AND TISSUES

New York, New York 10036

March 23, 2007

Mail Stop: Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make the

following documents of record in the above-identified patent application:*

UNITED STATES PATENTS

Applicant	Patent No.	Issue Date
Rubenstein et al. Mahant et al.	3,875,011 5,624,813	April 1, 1975 April 29, 1997
Klaus et al.	6,284,787	September 4, 2001

^{*} A completed form PTO/SB/08 listing these documents is attached hereto together with copies of all non-United States patent documents listed thereon.

FOREIGN PATENT DOCUMENTS

Country/Office	Publication No.	<u>Publication Date</u>
EP	EP 1182259	February 27, 2002
PCT	WO 04/21000	March 11, 2004
PCT	WO 04/13347	February 12, 2004

OTHER DOCUMENTS

Anderson et al., "A fluorimetric method for measurement of erythrocyte transketolase activity," *Annals of Clinical Biochemistry*, 23: 180-189 (1986).

Cascante et al., "Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation," *Nutrition and Cancer*, 36: 150-154 (2000).

Comin-Anduix et al., "The effect of thiamine supplementation on tumour proliferation: A metabolic control analysis study," *Eur. J. Biochem.*, 268: 4177-4182 (2001).

De Bersaques, "Enzymes of carbohydrate metabolism in human epidermal tumors part 4 enzymes of the pentose phosphate pathway," *Journal of Cutaneous Pathology*, 2: 246-253 (1975).

De Bersaques, "Enzymes of carbohydrate metabolism in naevoid basal-cell epithelioma," *Arch. Derm. Res.*, 256: 103-111 (1976).

De Bersaques, "Enzymes of carbohydrate metabolism in human epidermal tumors. 1. lactate, malate, and isocitrate dehydrogenases, alanine and aspartate aminotransferases," *J. Cutaneous Path.*, 1: 103-108 (1974).

Lib et al., "Immunocapture and microplate-based activity measurement of mammalian pyruvate dehydrogenase complex," *Analytical Biochemistry*, 314: 121-127 (2003).

Rex et al., "Bioavailability of reduced nicotinamide-adenin-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy," *Pharmacology and Toxicology*, 90: 220-225 (2002).

Robb-Gaspers et al., "Coupling between cytosolic and mitochondrial calcium oscillations: role in the regulation of hepatic metabolism," *Biochimica et Biophysica Acta*, 1366: 17-32 (1998).

Smeets et al., "A NADH-dependent transketolase assay in erythrocyte hemolysate," *Clinica Chimica Acta*, 33: 379-386 (1971).

Vincent et al., "D-xylulose-induced depletion of ATP and Pi in isolated rat hepatocytes," *FASEB J.*, 3: 1855-1861 (1989).

Zimatkina et al., "Antitumor and antivitamin activity of oxythiamine disulfide," *Database Biosis Online, Biosciences Information Service*, Database accession no. PREV199799321912.

It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form PTO/SB/08, as considered and initialized by the Examiner, be returned with the next communication.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director of the United States Patent and Trademark Office is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075 (Order No. 001581-0281). A duplicate copy of this Statement is transmitted herewith.

An early and favorable action is respectfully requested.

Respectfully submitted,

Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants
Fish & Neave IP Group


Fish & Neave IP Group

ROPES & GRAY LLP Customer No. 1473

1211 Avenue of the Americas

New York, New York 10036

Tel.: (212) 596-9000 Fax: (212) 596-9090



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B	/PTO	•	Complete if Known		
000				Application Number	10/594,194	
IN	IFORMATIC	ON DISC	CLOSURE	Filing Date	September 25, 2006	
S	STATEMENT BY APPLICANT			First Named Inventor	May Han	
		_ ,		Art Unit	1657	
	(Use as many	sheets as ne	cessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	GEN/033	

U.S. PATENT/PUBLICATION DOCUMENTS							
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant		
	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear		
		US - 3,875,011	04-01-1975	Rubenstein et al.			
		US - 5,624,813	04-29-1997	Mahant et al.			
		US - 6,284,787	09-04-2001	Klaus et al.			

		FOREI	GN PATENT DO	CUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code³ -Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY		of Patentee or of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		EP 1182259	02-27-2002	Cirpus e	et al.		Г
		WO 04/021000	03-11-2004	Capaldi	et al.		
		WO 04/013347	02-12-2004	Berghs	et al.		
							L
							Ļ
							<u> </u>
							L
				· · · · · · · · · · · · · · · · · · · ·			├-
							
	-			-			┝
							-
							\vdash
Examin Signatu					Date Considered	<u> </u>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, 2313-1450. 3345693 1

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

Sub	ostitute for form 1449A/B/PT	о		Complete if Known		
		_		Application Number	10/594,194	
11	NFORMATION	N DI	SCLOSURE	Filing Date	September 25, 2006	
S	STATEMENT BY APPLICANT			First Named Inventor	May Han	
				Art Unit	1657	
	(Use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	GEN/033	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Anderson et al., "A fluorimetric method for measurement of erythrocyte transketolase activity," <i>Annals of Clinical Biochemistry</i> , 23: 180-189 (1986).	
		Cascante Marta et al., "Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation," <i>Nutrition and Cancer</i> , 36: 150-154 (2000).	
		Comin-Anduix Begona et al., "The effect of thiamine supplementation on tumour proliferation: A metabolic control analysis study," <i>Eur. J. Biochem.</i> , 268: 4177-4182 (2001).	
		De Bersaques, "Enzymes of carbohydrate metabolism in human epidermal tumors part 4 enzymes of the pentose phosphate pathway," <i>Journal of Cutaneous Pathology</i> , 2: 246-253 (1975).	
		De Bersaques, "Enzymes of carbohydrate metabolism in naevoid basal-cell epithelioma," <i>Arch. Derm. Res.</i> , 256: 103-111 (1976).	
		De Bersaques, "Enzymes of carbohydrate metabolism in human epidermal tumors. 1. lactate, malate, and isocitrate dehydrogenases, alanine and aspartate aminotransferases," <i>J. Cutaneous Path.</i> , 1: 103-108 (1974).	
		Lib et al., "Immunocapture and microplate-based activity measurement of mammalian pyruvate dehydrogenase complex," <i>Analytical Biochemistry</i> , 314: 121-127 (2003).	
		Rex et al., "Bioavailability of reduced nicotinamide-adenin-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy," <i>Pharmacology and Toxicology</i> , 90: 220-225 (2002).	

Examiner	Date	
Signature	 Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, 2313-1450. 3345693 1



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449A/B/P	то		Complete if Known		
				Application Number	10/594,194	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	September 25, 2006	
S	STATEMENT BY APPLICANT			First Named Inventor	May Han	
				Art Unit	1657	
	(Use as many s	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	GEN/033	

	NON PATENT LITERATURE DOCUMENTS	
	Robb-Gaspers et al., "Coupling between cytosolic and mitochondrial calcium oscillations: role in the regulation of hepatic metabolism," <i>Biochimica et Biophysica Acta.</i> , 1366: 17-32 (1998).	
	Smeets et al., "A NADH-dependent transketolase assay in erythrocyte hemolysate," Clinica Chimica Acta, 33: 379-386 (1971).	
	Vincent et al., "D-xylulose-induced depletion of ATP and Pi in isolated rat hepatocytes," FASEB J., 3: 1855-1861 (1989).	
	Zimatkina et al., "Antitumor and antivitamin activity of oxythiamine disulfide," Database Biosis Online, Biosciences Information Service, Database accession no. PREV199799321912.	
		ļ
i		

Examiner	-	Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, 3345693 1 2313-1450.